Effient Loading Dose
The recommended loading dose of Effient (prasugrel) is 60 mg orally as a single dose, followed by a maintenance dose of 10 mg once daily. 1
Standard Dosing
- Loading dose: 60 mg orally (single dose)
- Maintenance dose: 10 mg orally once daily
- Concomitant aspirin: 75-100 mg daily (or up to 325 mg if needed initially) 2, 1
This dosing is consistent across both the 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines 2 and the 2020 ESC guidelines 3, as well as the FDA-approved labeling 1.
Dose Modifications for Specific Populations
Low Body Weight (<60 kg)
- Loading dose: 60 mg (unchanged)
- Maintenance dose: Consider reducing to 5 mg daily 2, 1
- Rationale: Increased drug exposure and bleeding risk in lighter patients, though the 5 mg dose has not been prospectively validated 1, 4
Elderly (≥75 years)
- Loading dose: 60 mg (if used)
- Maintenance dose: 5 mg daily if treatment deemed necessary 2, 3
- Important caveat: Prasugrel is generally not recommended in patients ≥75 years due to increased risk of fatal and intracranial bleeding, except in high-risk situations (diabetes or prior MI) where benefit may outweigh risk 1
Timing Considerations
The timing of the loading dose matters significantly:
NSTE-ACS: In the pivotal TRITON-TIMI 38 trial, prasugrel loading was delayed until coronary anatomy was established 1. A subsequent trial showed no clear benefit when prasugrel was given before diagnostic angiography compared to at PCI, but bleeding risk increased with early administration, particularly in patients requiring urgent CABG 1
STEMI (presenting >12 hours): Load after coronary anatomy is known 1
STEMI (presenting ≤12 hours): Loading dose can be given at time of diagnosis, though most patients in trials received it at time of PCI 1
Clinical pearl: The substantial bleeding risk in patients requiring urgent CABG after prasugrel loading argues for delaying administration until coronary anatomy is established and PCI is confirmed, particularly in NSTE-ACS 1.
Contraindications to Consider Before Loading
Do not give prasugrel if:
- Prior TIA or stroke (any time) - absolute contraindication 1
- Active pathological bleeding 1
- Likely to require urgent CABG - discontinue at least 7 days before surgery if possible 1
Evidence Quality
The 60 mg loading dose is supported by the landmark TRITON-TIMI 38 trial (13,608 patients), which demonstrated superior efficacy versus clopidogrel (9.9% vs 12.1% primary endpoint, HR 0.81, p<0.001) but increased major bleeding (2.4% vs 1.8%) 5. This dosing has been incorporated into the most recent 2025 ACC/AHA guidelines 2 and remains consistent with 2020 ESC recommendations 3.
The 60 mg loading dose followed by 10 mg daily maintenance (with dose reduction to 5 mg for weight <60 kg or age ≥75 years in selected cases) represents the evidence-based standard for prasugrel initiation in ACS patients undergoing PCI.